Get the Stockscreener App
4.60
6.12%
-0.30
Opgen Inc stock is traded at $4.60, with a volume of 1,319.
It is down -6.12% in the last 24 hours and down -6.12% over the past month.
See More
Previous Close:
$4.90
Open:
$3.7
24h Volume:
1,319
Relative Volume:
8.33
Market Cap:
$N/A
Revenue:
$1.96M
Net Income/Loss:
$-9.40M
P/E Ratio:
-0.2652
EPS:
-17.346
Net Cash Flow:
$-6.31M
1W Performance:
-6.12%
1M Performance:
-6.12%
6M Performance:
-57.97%
1Y Performance:
+14.04%
1-Day Range:
$3.70
$4.60
1-Week Range:
$3.70
$4.60
52-Week Range:
$3.70
$4.98
Opgen Inc Stock (OPGN) Company Profile
Compare OPGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPGN
Opgen Inc
|
4.60 | 0 | 1.96M | -9.40M | -6.31M | -17.35 |
|
ABT
Abbott Laboratories
|
130.57 | 232.02B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.23 | 151.51B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
388.76 | 148.85B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.19 | 113.49B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.08 | 44.81B | 5.54B | 4.18B | 623.10M | 7.00 |
Opgen Inc Stock (OPGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-19 | Initiated | Alliance Global Partners | Buy |
| Feb-07-18 | Reiterated | H.C. Wainwright | Buy |
| Jun-29-16 | Initiated | Rodman & Renshaw | Buy |
Opgen Inc Stock (OPGN) Latest News
Pivot Bio Expands Growth Office to Accelerate Strategic Partnerships, Digital Enablement and Global Market Expansion - The Malaysian Reserve
Infection Surveillance Solutions Market Generated - openPR.com
Near Patient Molecular Solution Market Is Booming Worldwide | - openPR.com
OpGen Forms Joint Venture with European Bank - TipRanks
OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com - Defense World
Fortrea (NASDAQ:FTRE) and OpGen (NASDAQ:OPGN) Head-To-Head Review - Defense World
OpGen Delays 10-Q Filing Amid Operational Challenges - TipRanks
OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com - Defense World
OpGen, Inc. to Host Earnings Call - ACCESS Newswire
OpGen Subsidiary Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for U.A.E. and Qatar - Barchart.com
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN) - Defense World
StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN) - Defense World
OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com - Defense World
OpGen (NASDAQ:OPGN) Shares Pass Above 50-Day Moving Average – Time to Sell? - Defense World
OpGen (NASDAQ:OPGN) Now Covered by StockNews.com - Defense World
OpGen Delays Yearly Report Amid Operational Challenges - TipRanks
Antimicrobial Susceptibility Testing Market Expecting Huge Demand in Upcoming Years Accelerate Diagnostics - openPR.com
Antimicrobial Resistance Surveillance Global Market Report 2025: Steady Growth, And Increased Awareness Propel - EIN News
OpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.com - Defense World
Blood Culture Tests Market Size is Projected to Reach USD - GlobeNewswire
Blood Culture Screening Devices Market Rewriting its Growth Cycle | bioMérieux SA, OpGen, T2 Biosystems - Newstrail
Antimicrobial Resistance Surveillance Market is expected to generate a revenue of USD 9.86 Billion by 2032, Globally, at 5.65% CAGR: Verified Market Research - The Malaysian Reserve
Antimicrobial Resistance Surveillance Market is expected to generate a revenue of USD 9.86 Billion by 2032, Globally, at 5.65% CAGR: Verified Market Research® - PR Newswire UK
Blood Stream Infection Testing Global Market Report 2025: Trends, Forecasts, and Competitor Analysis - EIN News
Blood Culture Test Market to Reach $8.18 Billion | CAGR of 9.3% - openPR
Global Antimicrobial Resistance Surveillance Market to Reach USD 9.50 Billion by 2032, Growing at a CAGR of 5.47% - WICZ
OpGen Faces Delisting from Nasdaq Following Appeal Decision - Defense World
OpGen faces Nasdaq delisting, to trade OTC - Investing.com
Electronic evaluation of infection risk from room environment and - ResearchGate
OpGen Inc sees significant stock purchase by AEI Capital Ltd - Investing.com
OpGen Inc adds new COO and Company Secretary - Investing.com
Lineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
OpGen secures additional $6 million financing, extends agreement to 2025 - Investing.com India
AEI Capital Ltd reports stock transactions in OpGen Inc - Investing.com
TG Investment Ltd. Take up 7% Stake in OpGen, Inc. with Shares Traded Across Multiple Exchanges - Barchart
OpGen’s Strategic Moves Amid Nasdaq Delisting and New Financing - TipRanks
OpGen Inc appoints five new directors to its board - Investing.com
Opgen Inc Stock (OPGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.54%
0.19%
Cap:
|
Volume (24h):